Delivery Order HHSN261201200021I-HHSN26100002

The University of Oklahoma is the prime contractor for this $493,001 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program IDIQ vehicle held by the National Cancer Institute. The order calls for further testing of a multi-peptide KRAS vaccine for pancreatic cancer prevention, with objectives to determine efficacy in a genetically engineered mouse model and evaluate immune responses to establish correlates of antitumor protection. Major subcontractors include...

This federal contract was awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (HHS), to the University of Oklahoma (OU) to support the PREVENT Preclinical Drug Development Program. The $884,341.08 firm-fixed-price contract task order is for the development of an EGFR and KRAS vaccine to prevent lung cancer. Key subcontractors include The Methodist Hospital (doing business as Houston Methodist Hospital) and the Medical College of Wisconsin. The...

This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $1,259,678.78 contract is to provide support for the preclinical development of an endoxifen gel, including pharmacology, toxicology, and safety studies to support an Investigational New Drug (IND) application. This contract is part of the NCI's PREVENT...

This is a $712,240 firm fixed-price delivery order awarded to SRI International, a non-profit research and development institute, by the National Cancer Institute (NCI). The contract is part of the NCI's Preclinical Prevention Cancer Program and supports the "Optimization and Further Development of Mesothelin Vaccine for the Prevention of Ovarian Cancer" project. This R&D effort focuses on basic biomedical research towards developing a preventive vaccine for ovarian cancer. The...

This federal contract was awarded by the National Cancer Institute (NCI), a civilian agency under the Department of Health and Human Services, to the University of Oklahoma (OU). The $1,891,140.00 firm fixed price delivery order is for a program titled "PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS" and is focused on developing a novel mRNA vaccine to prevent triple negative breast cancer. The contract has an ultimate...

This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the U.S. government, to the University of Wisconsin System. The $1,214,305 contract is for a Phase I clinical trial to evaluate the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) that targets three breast cancer antigens (IGFBP-2, HER2, and IGF-IR). The contract is part of NCI's Cancer Prevention Agent Development Program, which focuses on early-stage clinical research. The...

This is a delivery order issued under the PREVENT Preclinical Drug Development Program contract, a $150 million multiple-award indefinite delivery/indefinite quantity (IDIQ) contract with the National Cancer Institute (NCI). The award to the IIT Research Institute (IITRI), a non-profit division of the Illinois Institute of Technology, is for the preclinical development of an RNA vaccine for immunoprevention of prostate cancer. The total value of this specific task order is $1,742,384.00. IITRI...

The National Cancer Institute, a component of the Department of Health and Human Services' National Institutes of Health, awarded an $849,440 firm fixed price contract to the University of Oklahoma Health Sciences Center under the Prevent Preclinical Drug Development Program. The University will deliver on the stated objective of chemoprevention with aerosolized let-7 microRNA in mouse models of non-small cell lung cancer adenocarcinoma and squamous cell carcinoma. Two subcontracts were issued...

This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Illinois. The contract is valued at $761,043.02 and is part of the larger "Toxicology of Drugs Developed for Cancer Patients" indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The purpose of this award is to conduct pre-clinical toxicology studies of a drug candidate, specifically DNA methyltransferase-TdCyd, for potential use in...

This federal contract award, valued at $1,113,527.00, was issued by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to the University of Oklahoma (OU) to support the PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM. The contract tasks OU, a public research university, with developing a novel multi-antigen vaccine (TNBCVAX) to prevent triple negative breast cancer. This work is being performed under a Delivery Order contract that is part...